Assessment of microglial activation in patients with schizophrenia stratified for C4 complement by PET using [18F]DPA-714

Prior treatment

• Participation in research or management of a pathology with ionizing radiation exposure as part of a nuclear medicine examination (PET, SPECT, NM) in the year prior to or during the exclusion period of another research

Other illness

• Progressive chronic inflammatory disease (rheumatic, digestive, autoimmune)
• For healthy volunteers only : Pathology or history of Axis 1 psychiatric pathology investigated by the validated French version of the MINI (Mini International Neuropsychiatric Interview) questionnaire
• Known hypersensitivity to radiopharmaceutical ([18F]DPA-714 or one of the excipients)
• History of severe renal or liver failure

Lab values

• Contraindication to MRI : pacemaker or neurosensory pacemaker or implantable defibrillator; clip on an aneurysm or clip on a vascular malformation of the brain; ferromagnetic intraocular or cerebral foreign body; prosthesis or ferro-metallic objects or fragments mobilizable magnetic; cochlear implants; peripheral stimulator; ventriculoperitoneal neurosurgical bypass valves; permanent eye or lip makeup. Automatic injection device type insulin pump, blood glucose sensor

Other

• Adult subject to legal protection (guardianship of a tutor, or safeguard of justice)
• Claustrophobia
• Current pregnancy, breastfeeding
• Person refusing to be informed of a significant health finding discovered in the research
• Person deprived of liberty by administrative or judicial decision

• Male or Female, aged from 18 to 55, patients with schizophrenia diagnostic according to DSM-5 and presenting HLA 8.1 AH haplotype (8.1 AH+) or presenting no HLA 8.1 AH haplotype ( (8.1 AH-)
• Male or Female healthy controls aged from 18 to 55 matched regarding age, sex, HLA/C4 according to patients (8.1 AH+ or 8.1 AH-).
• Having Efficient Contraception for women of reproductive age ( contraception will be considered effective from the moment the patient declares the use of an oral contraceptive, the presence of an IUD other than copper ones, a diaphragm or a contraceptive implant, or the completion of a tubal ligation or sterilization by Essure process)
• Be able to understand research objectives and procedures
• Be affiliated with or be a beneficiary of a social security scheme
• Genetic criterion: TSPO genotype allowing tracer fixation (90% of subjects)
• Have signed a free and informed consent